Humana (HUM) Q2 2026 earnings review
Explosive Growth Masks an Impending Profitability Cliff
Humana delivered a solid 26Q2, with Adjusted EPS of $7.61 beating its own targets and total revenues surging 26% YoY to $40.8B. This was fueled by massive individual Medicare Advantage (MA) growth (+23% YTD). However, the back half of the year looks brutal. Management slashed FY26 GAAP EPS guidance to $6.52 (from $8.36) and warned that 26Q3 will generate a net loss (Adjusted EPS of ~$1.00) as the Star Ratings headwind ($3.5B) takes full effect and benefit ratios spike above 94%. The company is trading near-term margin for market share, betting heavily on a 2028 turnaround.
🐂 Bull Case
The massive influx of MA members is driving significant scale. Consolidated operating cost ratio improved 120 basis points YoY to 9.8%, proving management's transformation and efficiency initiatives are working.
CenterWell Primary Care patients grew 27% YTD to 622,000. This agnostic expansion is reducing the company's reliance purely on its own insurance pool and driving higher margin services revenue.
🐻 Bear Case
The $3.5B Star Ratings penalty is forcing a reversing trend in profitability. Q3 Adjusted EPS is guided to reverse into negative territory (-$1.00), a drastic shift from the profitable first half.
Management explicitly warned that the gap between MA funding and medical cost trends is larger for 2027 than 2026. This will force benefit cuts, risking the massive membership gains they just acquired.
⚖️ Verdict: 🔴
Bearish. While top-line and membership growth are accelerating, the fundamental economics of the core MA product are deteriorating. Slashed GAAP guidance, an impending Q3 loss, and the necessity to cut benefits in 2027 outweigh the impressive cost leverage and CenterWell growth.
Key Themes
2027 Bid Strategy: Margin Over Membership
Humana's core macro problem is a widening gap between Medicare Advantage funding and underlying medical cost trends. Management admitted this gap is 'clearly larger' for 2027. To protect the promised 3% margin target for 2028, Humana will be forced to cut member benefits in upcoming bids. This creates a high risk of elevated member churn next year.
CenterWell Execution and Expansion
CenterWell continues to be a primary growth engine, accelerating its expansion. Primary care patients jumped 27% to 622,000, aided by the MaxHealth and Villages Health acquisitions. Furthermore, CenterWell Pharmacy partnered with Cost Plus Drugs to develop employer prescription solutions, demonstrating specific product innovation outside traditional MA.
Relentless Operating Cost Leverage
The company's 'value creation initiatives' and massive membership influx are driving a stable, yet improving, cost structure. The consolidated operating cost ratio dropped from 11.0% in 25Q2 to 9.8% in 26Q2. Management is successfully outsourcing shared services and executing vendor consolidation to protect margins.
Looming Welsh Carson Put Option
A specific data point revealed in the Q&A contradicts the narrative of unconstrained balance sheet strength: Humana faces a massive potential cash outflow. If Welsh Carson exercises its put option on the 2025 clinic cohort in 2027, Humana will owe $1.0 billion to $1.5 billion in cash. While management states this is 'in their funding plan,' it restricts future capital flexibility.
Membership Surge Defying the Industry
Humana is absorbing market share aggressively. Individual MA membership is up 23% YTD (1.2M additions), and Stand-alone PDP is up 50% (1.1M additions). While this pressures near-term margins, it radically expands the total addressable pool for CenterWell's clinical and pharmacy services over the next 3-5 years.
V28 Risk Model Pressures CenterWell Margins
Despite top-line growth, CenterWell's operating cost ratio remains elevated at 92.4%. Management cited the phase-in of the CMS v28 risk model revision as an ongoing headwind. If clinical productivity improvements fail to offset this regulatory change, CenterWell's profit contribution will decelerate.
Other KPIs
Accelerating significantly from $1.60B in the prior year. This was heavily influenced by favorable working capital dynamics, including a $1.05B Medicaid state-directed payment that boosted parent company cash.
Stable sequentially (down 0.8 days from 26Q1) but decelerating heavily from 36.5 days a year ago. The decline reflects a structural shift toward prescription drug expenses (which process faster than medical claims) due to the Inflation Reduction Act, resulting in lower IBNR balances.
Stable. Down slightly from 43.0% in Q1 but remains slightly above the company's long-term target of 40%. Management secured $1.5B in pre-capitalized trust securities (P-Caps) to ensure contingent liquidity without immediately expanding the debt load.
Guidance
Decelerating violently. Management revised this down massively from the prior 'at least $8.36' guide. The cut is driven by non-cash put/call valuation adjustments tied to primary care partnerships and impairment charges.
Stable. The company maintained its core operational earnings target, highlighting that the $3.5B Star Ratings penalty was already priced into this depressed baseline (down from $17.14 in FY25).
Reversing. The company expects to lose money on an adjusted basis in the third quarter, a drastic shift from $7.61 in Q2. This perfectly illustrates the brutal seasonality inflicted by the Star Ratings revenue gap.
Stable vs previous guidance, but structurally elevated compared to historical norms. The 26Q3 metric is expected to spike 'slightly above 94%'.
Accelerating. Reaffirmed expectations to grow individual MA by roughly a quarter of its base, banking millions of new lives to funnel into value-based care over the next three years.
Key Questions
2027 Benefit Cuts vs. Retention
Given the 'clearly larger' funding gap for 2027, how aggressive will the benefit reductions be, and what is your internal modeling for member churn resulting from these cuts?
Welsh Carson Put Option Impact
With the potential $1B-$1.5B cash outflow in 2027 for the Welsh Carson put option, how does this restrict your ability to aggressively resume share buybacks or pursue further M&A in the CenterWell segment?
Visibility into New Member Acuity
You absorbed roughly 1.2 million new MA members this year. As Q2 claims mature, are the acuity and IBNR requirements for these specific 'switchers' and 'bounce-backs' matching your initial pricing models?